Silexion Therapeutics (NASDAQ:SLXN) Releases Quarterly Earnings Results

Silexion Therapeutics (NASDAQ:SLXN) issued its quarterly earnings results on Wednesday. The company reported ($2.88) EPS for the quarter, Zacks reports.

Silexion Therapeutics Price Performance

Shares of NASDAQ:SLXN traded down $0.01 on Wednesday, reaching $2.81. 21,114 shares of the company traded hands, compared to its average volume of 452,247. The stock has a market capitalization of $8.77 million, a PE ratio of -0.01 and a beta of -0.07. The company has a debt-to-equity ratio of 26.58, a current ratio of 2.44 and a quick ratio of 2.44. The company’s 50 day moving average is $3.88 and its 200-day moving average is $9.12. Silexion Therapeutics has a fifty-two week low of $2.66 and a fifty-two week high of $63.45.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $75.00.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.